After hanging out the for sale sign and filing for bankruptcy earlier this year, the genetic testing provider Invitae has found a new home for its portfolio at Labcorp. The two companies announced ...

Shares of Invitae are trading for less than a nickel apiece after a report surfaced earlier this week claiming the genetic testing company is on the verge of filing for bankruptcy. The report came ...

Invitae has made progress in its business realignment plan, cutting cash burn by one-half from 2022 to 2023. However, the company still faces significant challenges. Invitae shares have lost more than ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

San Francisco-based genetic diagnostics company Invitae has acquired Good Start Genetics and CombiMatrix, expanding Invitae’s portfolio to include prenatal and pediatric testing. It’s part of their ...

The long term profitability and success of any company is highly dependent on the market in which it operates. Many markets have low barriers to entry; many sellers offer undifferentiated products, ...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will ...

Genetic testing company Invitae has made more than a dozen acquisitions to further its goal of democratizing genetic testing. Its latest deal, a $325 million bid to acquire Ciitizen, will add patients ...

Medical genetics firm Invitae (NYSE:NVTA) suffered a shocking fall from grace as insider reports point to an upcoming bankruptcy filing. Although the company forwarded a compelling concept — ...

Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

Invitae (NYSE: NVTA) shares have plummeted more than 80% this year. The genetic testing company has grown revenue over the years, but it hasn't been able to turn that revenue into profit. Instead, ...